EGFR and lung adenocarcinoma: In order to validate our findings in an additional model of resistance to EGFR TKIs, we used six p.T790M-negative gefitinib-resistant lines (GR1–GR6), derived from 11–18 lung adenocarcinoma cells, which had been previously established in our laboratory (Table 3)25.